Adagene Inc

NASDAQ ADAG

Data sourced from

and

Download Data

Adagene Inc Current Liabilities to Total Liabilities Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending December 31, 2023: 19.83%

Adagene Inc Current Liabilities to Total Liabilities Ratio 3 year CAGR is 19.83% for the Trailing 12 Months (TTM) ending December 31, 2023. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Adagene Inc Current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.89, a 137.97% change year over year.
Adagene Inc Current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.37, a -7.69% change year over year.
Adagene Inc Current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 0.40.

NASDAQ: ADAG

Adagene Inc

CEO	Dr. Peter P. Luo Ph.D.
IPO Date	Feb. 9, 2021
Location	China
Headquarters	Building C14, Suzhou, China, 215123
Employees	174
Sector	Healthcare
Industry	Biotechnology

Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Key trends